One of the more spurious and naive arguments proffered by the industry's antagonists and even some people in government is that the pricing of new treatments should reflect whether public funding contributed in any way to its development. …
Latest Video
New Stories
-
Omico opens a new chapter in precision oncology research
June 1, 2026 - - Latest News -
Ex-MA executive named the first CEO of Medicinal Cannabis Council Australia
June 1, 2026 - - Latest News -
Oral RAS inhibitor doubles median survival and cuts death risk in metastatic pancreatic cancer
June 1, 2026 - - Latest News -
Australia risks losing more than jobs in its biopharmaceutical sector — it risks losing strategic capability
June 1, 2026 - - Latest News -
New PBS listings expand access to blood cancer therapies
June 1, 2026 - - Latest News -
Now you can see the next step in the process most are officially excluded from
June 1, 2026 - - Latest News -
Australia's HTA Review closed-loop process continues with 'Delphi' stage two
June 1, 2026 - - Latest News